Company Quick10K Filing
PowerVerde
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-03-29
10-Q 2018-09-30 Filed 2018-11-09
10-Q 2018-06-30 Filed 2018-08-13
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-04-17
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-12
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-10
10-Q 2016-03-31 Filed 2016-05-12
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-10
10-Q 2015-06-30 Filed 2015-08-11
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-03-16
10-Q 2014-09-30 Filed 2014-11-07
10-Q 2014-06-30 Filed 2014-08-12
10-Q 2014-03-31 Filed 2014-05-13
10-K 2013-12-31 Filed 2014-03-17
10-Q 2013-09-30 Filed 2013-11-08
10-Q 2013-06-30 Filed 2013-08-12
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-05-16
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-07-11
10-K 2011-12-31 Filed 2012-04-16
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-22
10-Q 2011-03-31 Filed 2011-05-23
10-K 2010-12-31 Filed 2011-04-07
10-Q 2010-09-30 Filed 2010-11-15
10-Q 2010-06-30 Filed 2010-08-17
10-Q 2010-03-31 Filed 2010-05-24
10-K 2009-12-31 Filed 2010-04-14

PowerVerde Financials

PWVI Metrics, Comps, Filings

Quarterly | Annual

Business

Vyrex Corporation (“Vyrex” or the “Company”) was incorporated in Nevada in 1991 and operated as a research and development stage company seeking to discover and develop pharmaceuticals, nutraceuticals and cosmeceuticals for the treatment and prevention of respiratory, cardiovascular and neurodegenerative diseases and conditions associated with aging (the “Biotech Business”). The Biotech Business was unsuccessful and, as a result, the Company ceased material operations relating to that business in October 2005; however, the Company retained its intellectual property rights and contract rights relating to that business (the “Biotech IP”). On October 17, 2005, the Company reincorporated in Delaware.

On February 11, 2008, Vyrex, PowerVerde, Inc. (“PowerVerde”) and Vyrex Acquisition Corporation (“VAC”), a wholly-owned subsidiary of Vyrex, all Delaware corporations, entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, on February 12, 2008, VAC merged with and into PowerVerde, with PowerVerde remaining as the surviving corporation and a wholly-owned subsidiary of Vyrex (the “Merger”). As consideration for the Merger, as of the closing of the Merger, each issued and outstanding share of common stock of PowerVerde was converted into the right to receive 1.2053301 shares of the common stock of Vyrex and each share of VAC was converted into one share of PowerVerde common stock. As a result of the Merger, the former shareholders of PowerVerde held 95% of the common stock of Vyrex.

On August 6, 2008, at a special meeting of shareholders, Vyrex's name was changed to “PowerVerde, Inc.” Simultaneously, the name of our operating company, PowerVerde, Inc., was changed to “PowerVerde Systems, Inc.”


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Innovus Pharmaceuticals (INNV) 5,796 65% -2.1 -63% 9,514 11,510 17,966 11,617 -5,984 -3,875 8,027
Blake Insomnia Therapeutics (BKIT) 3,681 -135.2 0 237 0 0 -27 -27 3,681
Geospatial (GSPH) 3,709 70% -6.3 -736% 111 3,656 273 190 -816 -586 3,668
Visium Technologies (VISM) 0 0.0 -31,116% 3 3,141 0 0 -796 -796 -3
Cartesian (CRTN) 3,632 30% -0.4 -44% 16,522 17,461 47,555 14,053 -7,270 -5,582 2,087
GraniteShares Platinum Trust (PLTM) 5,316 12.8 7% 5,803 2 0 0 415 415 5,316
Invesco CurrencyShares Singapore Dollar Trust (FXSG) 3,628 0% -50.4 1% 3,558 1 40 0 26 26 -1,288
Fieldpoint Petroleum (FPP) 3,628 0% 13.8 -5% 4,528 6,259 1,668 0 -241 247 3,414
American Church Mortgage (ACMC) 3,339 2.4 -0% 39,246 28,836 0 0 -48 1,343 3,218
Immune Pharmaceuticals (IMNP) 3,597 -0.9 -71% 20,716 19,874 0 0 -14,715 -13,953 12,494
American Bio Medica (ABMC) 3,580 35% -28.9 -20% 2,246 2,809 2,776 971 -440 -177 5,119
Empire Petroleum (EMPR) 3,576 0% -3.0 -30% 11,795 13,670 4,941 0 -3,541 -3,815 11,553
Genesis Financial (GFNL) 3,571 0% -1.1 -155% 2,427 3,394 10 0 -3,756 -3,242 3,551
Frontier Oilfield Services (FOSI) 3,542 0% -5.7 -319% 868 11,161 646 0 -2,768 -2,021 11,479
Sauer Energy (SENY) 3,496 49% -2.8 -116% 1,092 291 30 15 -1,271 -1,239 3,494
PowerVerde (PWVI) 3,175 0% -8.5 -707% 60 342 9 0 -427 -404 3,424
Puradyn Filter Technologies (PFTI) 3,451 24% -14.2 -47% 2,470 12,620 1,278 303 -1,160 -826 11,763
Invesco CurrencyShares Chinese Renminbi Trust (FXCH) 3,414 0% 1,654.7 -0% 3,419 1 4 0 -13 -13 -21,003
Igen Networks (IGEN) 3,418 68% -2.6 -137% 604 2,437 594 405 -830 -1,315 3,381
Giggles N' Hugs (GIGL) 3,381 0% -17.2 -29% 1,185 3,455 1,931 0 -341 -196 3,378

Balance Sheet ($'000)2011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash23582211002045131077748378595381365486514713512937821811732
Accounts Receivable303450189155331222201411878917116910937016221010569
Inventory
PP&E1816143636368626255656158524845413733302622151285211000
Assets288673,5713,4253,68571256972264546639239235532822516426430326635226736334125650933422114310431013160
Accounts Payable
Long-Term Debt40279281
Liabilities2513605116171,057533544718611522493555562516467493587528509518460504370281245145339341322342
Stockholders' Equity37-2943,0602,8082,62817925434-56-102-164-207-188-242-329-323-225-243-165-193-141-28-2426332021514065-30-191-282
Income Statement ($'000)2011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue143191430341167110912950401267318917116913437916238513
Cost of Revenue1300000000000000
Gross Profit131914303411671109129504012673189
R&D237-43657729512532423677687915119546568595524355847178494847783835489713535115
SG&A3008332212712812054531901079415314813810911050536086121555558594650708948614950
Tax00000000000000000000000000
Net Income-526-382-787-540-375-3,052-596-176-120-163-286-129-143-8-5324-290-186-162505557428857-550-111-95-161-171
Cash Flow ($'000)2011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-227-236-132-284-10825-178-53-237-9650-54-120-19-3997348-12910594-49918493-92-57-111-84
Cash Investing-0000-56-2-140000-160000
Cash Financing04505230975125150252406800002531-49-49-500-25-100-100-50-1500026880